Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome

Abstract

Congenital heart diseases (CHDs), including hypoplastic left heart syndrome (HLHS), are genetically complex and poorly understood. Here, a multi-disciplinary platform was established to functionally evaluate novel CHD gene candidates, based on whole genome and iPSC RNA sequencing of a HLHS family-trio. Filtering for rare variants and altered expression in proband iPSCs prioritized 10 candidates. siRNA/RNAi-mediated knockdown in generic human iPSC-derived cardiomyocytes (hiPSC-CM) and in developing Drosophila and zebrafish hearts revealed that LDL receptor-related protein LRP2 is required for cardiomyocyte proliferation and differentiation. Consistent with hypoplastic heart defects, compared to patents the proband's iPSC-CMs exhibited reduced proliferation. Interestingly, rare, predicted-damaging LRP2 variants were enriched in a HLHS cohort; however, understanding their contribution to HLHS requires further investigation. Collectively, we have established a multi-species high-throughput platform to rapidly evaluate candidate genes and their interactions during heart development, which are crucial first steps towards deciphering oligogenic underpinnings of CHDs, including maladaptive left hearts.

Data availability

Sequencing data are deposited in the NCBI Sequence Read Archive (SRA) database with accession numbers: SRS1417684 (proband iPSCs), SRS1417685 (paternal iPSCs), SRS1417686 (maternal iPSCs), SRS1417695 (proband d25 differentiated cells), SRS1417696 (paternal d25 differentiated cells), SRS1417714 (maternal d25 differentiated cells)

The following previously published data sets were used

Article and author information

Author details

  1. Jeanne L Theis

    Cardiovascular Genetics Research Laboratory, Mayo Clinic, Rochester, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Georg Vogler

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8303-3531
  3. Maria A Missinato

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9055-758X
  4. Xing Li

    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Tanja Nielsen

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Xin-Xin I Zeng

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2707-7759
  7. Almudena Martinez-Fernandez

    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Stanley M Walls

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Anaïs Kervadec

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. James N Kezos

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Katja Birker

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Jared M Evans

    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Megan M O'Byrne

    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Zachary C Fogarty

    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5588-3216
  15. André Terzic

    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Paul Grossfeld

    Rady's Hospital, University of California San Diego, San Diego, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Karen Ocorr

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. Timothy J Nelson

    Department of Internal Medicine, Mayo Clinic, Rochester, United States
    For correspondence
    nelson.timothy@mayo.edu
    Competing interests
    The authors declare that no competing interests exist.
  19. Timothy M Olson

    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, United States
    For correspondence
    olson.timothy@mayo.edu
    Competing interests
    The authors declare that no competing interests exist.
  20. Alexandre R Colas

    Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  21. Rolf Bodmer

    Development, Aging, and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
    For correspondence
    rolf@sbpdiscovery.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9087-1210

Funding

Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, Mayo Clinic Foundation, Rochester, MN (SAN-233970)

  • Alexandre R Colas
  • Rolf Bodmer

National Institutes of Health (HL054732)

  • Rolf Bodmer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: SBP has retained the services of a veterinarian who is a diplomat of the American College of Laboratory Animal Medicine. Close contact with Animal Facility personnel is maintained through telephone calls and on-campus visits once a week. This person is a member of the Institute's Animal Care and Use Committee (IACUC)and attends monthly meetings. This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to the Institute's Animal Care and Use Program, which is accredited by AAALAC International, and a Multiple Project Assurance A3053-1 is on file in the OLAW, DHHS. The protocol was approved by SBP IACUC (Permit Number: 19-087). Animals are euthanized after filming hearts by an overdose of anesthetic (3-aminobenzoic acid ethyl ester (MS-222) at 250-300 mg/L.

Human subjects: Written informed consent was obtained for the index family and an HLHS cohort, under a research protocol approved by the Mayo Clinic Institutional Review Board (11-000114 "Genetic Investigations in Hypoplastic Left Heart Syndrome").

Copyright

© 2020, Theis et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,383
    views
  • 310
    downloads
  • 32
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jeanne L Theis
  2. Georg Vogler
  3. Maria A Missinato
  4. Xing Li
  5. Tanja Nielsen
  6. Xin-Xin I Zeng
  7. Almudena Martinez-Fernandez
  8. Stanley M Walls
  9. Anaïs Kervadec
  10. James N Kezos
  11. Katja Birker
  12. Jared M Evans
  13. Megan M O'Byrne
  14. Zachary C Fogarty
  15. André Terzic
  16. Paul Grossfeld
  17. Karen Ocorr
  18. Timothy J Nelson
  19. Timothy M Olson
  20. Alexandre R Colas
  21. Rolf Bodmer
(2020)
Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome
eLife 9:e59554.
https://doi.org/10.7554/eLife.59554

Share this article

https://doi.org/10.7554/eLife.59554

Further reading

    1. Genetics and Genomics
    2. Neuroscience
    Martina Rudgalvyte, Zehan Hu ... Dominique A Glauser
    Research Article

    Thermal nociception in Caenorhabditis elegans is regulated by the Ca²+/calmodulin-dependent protein kinase CMK-1, but its downstream effectors have remained unclear. Here, we combined in vitro kinase assays with mass-spectrometry-based phosphoproteomics to identify hundreds of CMK-1 substrates, including the calcineurin A subunit TAX-6, phosphorylated within its conserved regulatory domain. Genetic and pharmacological analyses reveal multiple antagonistic interactions between CMK-1 and calcineurin signaling in modulating both naive thermal responsiveness and adaptation to repeated noxious stimuli. Cell-specific manipulations indicate that CMK-1 acts in AFD and ASER thermo-sensory neurons, while TAX-6 functions in FLP thermo-sensory neurons and downstream interneurons. Since CMK-1 and TAX-6 act in distinct cell types, the phosphorylation observed in vitro might not directly underlie the behavioral phenotype. Instead, the opposing effects seem to arise from their distributed roles within the sensory circuit. Overall, our study provides (1) a resource of candidate CMK-1 targets for further dissecting CaM kinase signaling and (2) evidence of a previously unrecognized, circuit-level antagonism between CMK-1 and calcineurin pathways. These findings highlight a complex interplay of signaling modules that modulate thermal nociception and adaptation, offering new insights into potentially conserved mechanisms that shape nociceptive plasticity and pain (de)sensitization in more complex nervous systems.

    1. Genetics and Genomics
    Mengjia Li, Hengchao Zhang ... Lixiang Chen
    Research Article

    Isocitrate dehydrogenase 1 (IDH1) is the key enzyme that can modulate cellular metabolism, epigenetic modification, and redox homeostasis. Gain-of-function mutations and decreased expression of IDH1 have been demonstrated to be associated with pathogenesis of various myeloid malignancies characterized by ineffective erythropoiesis, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, the function and mechanism of IDH1 in human erythropoiesis still remains unclear. Here, utilizing the human erythropoiesis system, we present an evidence of IDH1-mediated chromatin state reprogramming besides its well-characterized metabolism effects. We found that knockdown IDH1 induced chromatin reorganization and subsequently led to abnormalities biological events in erythroid precursors, which could not be rescued by addition of reactive oxygen species (ROS) scavengers or supplementation of α-ketoglutarate (α-KG).We further revealed that knockdown IDH1 induces genome-wide changes in distribution and intensity of multiple histone marks, among which H3K79me3 was identified as a critical factor in chromatin state reprogramming. Integrated analysis of ChIP-seq, ATAC-seq, and RNA-seq recognized that SIRT1 was the key gene affected by IDH1 deficiency. Thus, our current work provided novel insights for further clarifying fundamental biological function of IDH1 which has substantial implications for an in-depth understanding of pathogenesis of diseases with IDH1 dysfunction and accordingly development of therapeutic strategies.